Austin Partner Susan Burnett authored an article for the DRI Drug and Medical Device Committee's newsletter, RX for the Defense. In "FDA vs. the First Amendment: The Future of the FDA's Broad Prohibition on Off-Label Promotion After Amarin," she dissects a New York federal court's ruling in Amarin Pharma, Inc. v. United States Food & Drug Administration, which upholds drugmakers' rights to truthfully promote their products' unapproved uses.